---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-005497"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-07-14T11:45:15+00:00"
generated_at: "2026-07-14T11:50:06.451052+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Valion Bio advances Entolimod platform with government engagement, 200x manufacturing scale-up, oncology expansion

## Summary
- Continued discussions with BARDA, NIAID, AFRRI, and U.S. Department of War for ARS preparedness and stockpile opportunities.
- Ukraine's Ministry of Health evaluating Entolimod for potential inclusion in national strategic reserves; no agreement yet.
- Demonstrated 200-fold manufacturing scale-up via Velocity Bioworks, producing ~1.3M potential human doses at 50L fermentation scale.
- Planning physician-sponsored studies of Entolimod in neutropenia; advancing next-gen TLR5 agonist Entolasta for oncology supportive care.
- Over $140M invested in Entolimod development to date; company building integrated platform across biodefense, manufacturing, and oncology.

## SEC filing metadata
- accession: 0001683168-26-005497
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-07-14T11:45:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826005497/0001683168-26-005497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826005497/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-005497
- JSON: https://secwatch.observer/filing/0001683168-26-005497.json
- Plain text: https://secwatch.observer/filing/0001683168-26-005497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.